Analysts take a look at GlaxoSmithKline plc (LON:GSK) having this to say.

October 13, 2018 - By Winifred Garcia

GlaxoSmithKline plc (LON:GSK) Logo

GlaxoSmithKline plc (LON:GSK) Ratings Coverage

Among 10 analysts covering GlaxoSmithKline PLC (LON:GSK), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. GlaxoSmithKline PLC had 50 analyst reports since April 23, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Friday, July 20 by Deutsche Bank. Barclays Capital maintained GlaxoSmithKline plc (LON:GSK) on Monday, April 23 with “Overweight” rating. The firm earned “Buy” rating on Thursday, July 26 by UBS. The stock of GlaxoSmithKline plc (LON:GSK) earned “Buy” rating by Liberum Capital on Wednesday, August 15. UBS maintained GlaxoSmithKline plc (LON:GSK) on Thursday, September 27 with “Buy” rating. The rating was maintained by Deutsche Bank on Tuesday, July 24 with “Hold”. The stock of GlaxoSmithKline plc (LON:GSK) earned “Neutral” rating by JP Morgan on Tuesday, August 21. The company was maintained on Friday, October 12 by Jefferies. The stock of GlaxoSmithKline plc (LON:GSK) has “Buy” rating given on Monday, September 10 by Shore Capital. The firm has “Hold” rating by Deutsche Bank given on Monday, October 8. Below is a list of GlaxoSmithKline plc (LON:GSK) latest ratings and price target changes.

12/10/2018 Broker: Jefferies Rating: Buy New Target: GBX 1580.00 Maintain
09/10/2018 Broker: Barclays Capital Rating: Overweight Old Target: GBX 1750.00 Maintain
08/10/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 1525.00 Maintain
27/09/2018 Broker: UBS Rating: Buy Old Target: GBX 1700.00 Maintain
24/09/2018 Broker: Barclays Capital Rating: Overweight Old Target: GBX 1750.00 Maintain
17/09/2018 Broker: Barclays Capital Rating: Overweight Old Target: GBX 1750.00 Maintain
10/09/2018 Broker: Shore Capital Rating: Buy Maintain
10/09/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 1700.00 Maintain
07/09/2018 Broker: Jefferies Rating: Buy Old Target: GBX 1775.00 New Target: GBX 1725.00 Maintain
06/09/2018 Broker: Deutsche Bank Rating: Hold New Target: GBX 1525.00 Maintain

The stock decreased 1.53% or GBX 22.2 during the last trading session, reaching GBX 1429.4. About 9.50M shares traded or 7.47% up from the average. GlaxoSmithKline plc (LON:GSK) has 0.00% since October 13, 2017 and is . It has underperformed by 15.62% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of 70.24 billion GBP. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 42.8 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Another recent and important GlaxoSmithKline plc (LON:GSK) news was published by Ft.com which published an article titled: “Nestlé, Unilever and Coca-Cola bid for GSK’s Horlicks unit” on September 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>